{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Deighan WI"],"funding":["NCATS NIH HHS","National Science Foundation, Division of Materials Research","National Institutes of Health, National Institute of General Medical Sciences","NCI NIH HHS","National Institutes of Health, National Cancer Institute","NIGMS NIH HHS"],"pagination":["653-661"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8055720"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["59(4)"],"pubmed_abstract":["<h4>Objectives</h4>Multiple myeloma (MM) is a malignant plasma cell neoplasm, requiring the integration of clinical examination, laboratory and radiological investigations for diagnosis. Detection and isotypic identification of the monoclonal protein(s) and measurement of other relevant biomarkers in serum and urine are pivotal analyses. However, occasionally this approach fails to characterize complex protein signatures. Here we describe the development and application of next generation mass spectrometry (MS) techniques, and a novel adaptation of immunofixation, to interrogate non-canonical monoclonal immunoproteins.<h4>Methods</h4>Immunoprecipitation immunofixation (IP-IFE) was performed on a Sebia Hydrasys Scan2. Middle-down <i>de novo</i> sequencing and native MS were performed with m"],"journal":["Clinical chemistry and laboratory medicine"],"pubmed_title":["Development of novel methods for non-canonical myeloma protein analysis with an innovative adaptation of immunofixation electrophoresis, native top-down mass spectrometry, and middle-down <i>de novo</i> sequencing."],"pmcid":["PMC8055720"],"funding_grant_id":["DMR-1644779","UL1 TR001422","P30 CA060553","P41GM108569","T32 GM105538","P41 GM108569","CCSG P30 CA060553"],"pubmed_authors":["McNicholl FP","Anderson LC","Deery MJ","Schachner LF","McLaughlin J","Murray D","Winton VJ","Barnidge D","Thomas PM","Gibson DS","Melani RD","Deighan WI","McGee JP","Kelleher NL","Alexander HD"],"additional_accession":[]},"is_claimable":false,"name":"Development of novel methods for non-canonical myeloma protein analysis with an innovative adaptation of immunofixation electrophoresis, native top-down mass spectrometry, and middle-down <i>de novo</i> sequencing.","description":"<h4>Objectives</h4>Multiple myeloma (MM) is a malignant plasma cell neoplasm, requiring the integration of clinical examination, laboratory and radiological investigations for diagnosis. Detection and isotypic identification of the monoclonal protein(s) and measurement of other relevant biomarkers in serum and urine are pivotal analyses. However, occasionally this approach fails to characterize complex protein signatures. Here we describe the development and application of next generation mass spectrometry (MS) techniques, and a novel adaptation of immunofixation, to interrogate non-canonical monoclonal immunoproteins.<h4>Methods</h4>Immunoprecipitation immunofixation (IP-IFE) was performed on a Sebia Hydrasys Scan2. Middle-down <i>de novo</i> sequencing and native MS were performed with m","dates":{"release":"2021-01-01T00:00:00Z","publication":"2021 Mar","modification":"2025-04-04T10:17:43.07Z","creation":"2025-04-04T10:17:43.07Z"},"accession":"S-EPMC8055720","cross_references":{"pubmed":["33079696"],"doi":["10.1515/cclm-2020-1072"]}}